Impact of European Association of Urology Combination and Platinum Eligibility on Real‐World Treatment Sequences and Survival in Japanese Patients With Metastatic Urothelial Carcinoma

Documenti analoghi

• Outcomes and Management of Dermatologic Toxicity Following Enfortumab Vedotin Rechallenge in Patients With Metastatic Urothelial Carcinoma: A Retrospective Single‐Center Study
  di: Takashi Kawahara, et al.
  Pubblicazione: (2026)
• The correlation between discrepancies in clinical and pathological T stages and overall survival in upper urinary tract urothelial carcinoma: Analysis of the hospital‐based cancer registry data in Japan
  di: Masanobu Shiga, et al.
  Pubblicazione: (2025)
• Improving Visualization via Polytetrafluoroethylene Mesh in 3D Computed Tomography Imaging After Laparoscopic Sacrocolpopexy
  di: Akane Yamaguchi, et al.
  Pubblicazione: (2025)
• Performance of Prognostic Models in Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin After Platinum‐Based Chemotherapy and Immune Checkpoint Inhibitors: YUSHIMA Study
  di: Hiroki Shimoda, et al.
  Pubblicazione: (2026)
• KL‐6 Mucin as Serum Tumor Marker of Metastatic Renal Cancer: A Case Report
  di: Kyohei Ishida, et al.
  Pubblicazione: (2024)